![]() | |
Clinical data | |
---|---|
Trade names | Gonazon |
Other names | 6-[3-(2-Naphthalenyl)-D-alanine]-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide; 6-[3-(2-Naphthalenyl)-D-alanine]-10-deglycinamide-luteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide |
Routes of administration | Implant; Injection |
Drug class | GnRH agonist |
Identifiers | |
| |
CAS Number |
|
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C65H82N18O13 |
Molar mass | 1323.484 g·mol−1 |
3D model ( JSmol) | |
| |
|
Azagly-nafarelin, sold under the brand name Gonazon, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in veterinary medicine in Europe. [1] [2] It is a GnRH analogue and a synthetic peptide, specifically a decapeptide. [1] [2] [3] The medication has been approved in Europe as a solid silicone-based matrix implant for use as a contraceptive in animals such as male dogs, cats, and others, but is no longer or was never commercially available. [1] [2] [4] [5] The medication has also been used to treat benign prostatic hyperplasia in animals. [6] [7] In addition to its use in mammals, azagly-nafarelin has been approved for use in aquaculture fish, specifically to control ovulation in salmonids, and was the first GnRH agonist to be available for use in fish. [2] [8] It was introduced for use by 2005. [9]
![]() | |
Clinical data | |
---|---|
Trade names | Gonazon |
Other names | 6-[3-(2-Naphthalenyl)-D-alanine]-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide; 6-[3-(2-Naphthalenyl)-D-alanine]-10-deglycinamide-luteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide |
Routes of administration | Implant; Injection |
Drug class | GnRH agonist |
Identifiers | |
| |
CAS Number |
|
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C65H82N18O13 |
Molar mass | 1323.484 g·mol−1 |
3D model ( JSmol) | |
| |
|
Azagly-nafarelin, sold under the brand name Gonazon, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in veterinary medicine in Europe. [1] [2] It is a GnRH analogue and a synthetic peptide, specifically a decapeptide. [1] [2] [3] The medication has been approved in Europe as a solid silicone-based matrix implant for use as a contraceptive in animals such as male dogs, cats, and others, but is no longer or was never commercially available. [1] [2] [4] [5] The medication has also been used to treat benign prostatic hyperplasia in animals. [6] [7] In addition to its use in mammals, azagly-nafarelin has been approved for use in aquaculture fish, specifically to control ovulation in salmonids, and was the first GnRH agonist to be available for use in fish. [2] [8] It was introduced for use by 2005. [9]